CHMP adopts positive opinion for treatment of acute angioedema attacks in children with hereditary angioedema with RUCONEST®
Update: Due to COVID-19 outbreak the Annual Report 2019 will be released on the 30th of March, the subsequent Conference Call will also be held on the 30th of March.
RUCONEST® (conestat alfa)
RUCONEST® (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of angioedema attacks in patients with HAE
View our financial calendar and what conferences, meetings and congresses we will visit in 2019 on our upcoming events page.
Our innovative technology and processes are aimed at purification and formulation of recombinant products. We are continuously looking for highly talented and motivated individuals to join our team.